ATNM revenueQ2 2026$35.00M
ATNM revenue was $35.00M in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was $90.0K.
Actinium Pharmaceuticals Inc. (Delaware) (ATNM) financials
For the twelve months ended Jun 30, 2026, Actinium Pharmaceuticals Inc. (Delaware) reported $35.09M of revenue and $11.31M of net income.
- Revenue, TTM
- $35.09M
- Net income, TTM
- $11.31M
- Net margin
- 32.2%
- EPS, diluted, TTM
- $0.35
- Cash
- $36.47M
- P/E
- 4.28
- P/S
- 1.38
- Market cap
- $48.4M
FY2021FY2025
FY2016FY2025
FY2016FY2025
ATNM revenue and earnings growth
ATNM net incomeQ2 2026$27.90M
ATNM net income was $27.90M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$6.88M a year earlier. For the full fiscal 2025 it was -$33.89M, compared with -$38.24M in fiscal 2024.
ATNM EPSQ2 2026$0.89
ATNM diluted EPS was $0.89 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.22 a year earlier. For the full fiscal 2025 it was -$1.09, compared with -$1.27 in fiscal 2024.
ATNM free cash flowQ2 2026-$5.66M
ATNM free cash flow was -$5.66M in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$24.68M, compared with -$33.08M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $90.0K | - | $81.0K | $1.03M | $1.14M | - | - | - | - | - |
| Cost of revenue | - | - | - | - | $900.0K | - | - | - | - | - |
| Gross profit | - | - | - | - | $244.0K | - | - | - | - | - |
| Research and development | $21.12M | $30.05M | $38.67M | $23.14M | $18.03M | $16.09M | $16.55M | $17.09M | $17.72M | $17.83M |
| Selling, general and admin | $15.21M | $12.08M | $13.33M | $12.00M | $8.08M | $6.31M | $5.52M | $6.73M | $9.19M | $9.02M |
| Operating income | -$36.25M | -$42.12M | -$51.92M | -$34.10M | -$24.96M | -$22.39M | -$22.07M | -$23.83M | -$26.91M | -$26.85M |
| Interest expense | - | - | - | - | - | - | - | - | - | $5.0K |
| Net income | -$33.89M | -$38.24M | -$48.82M | -$33.02M | -$24.77M | -$22.21M | -$21.90M | -$23.65M | -$26.60M | -$24.32M |
| EPS, basic | -$1.09 | -$1.27 | -$1.83 | -$1.37 | -$1.20 | -$1.83 | -$4.40 | -$6.60 | -$12.00 | -$15.00 |
| EPS, diluted | -$1.09 | -$1.27 | -$1.83 | -$1.37 | -$1.20 | -$1.83 | -$4.40 | -$6.60 | -$12.00 | -$15.00 |
| Diluted shares | 31.2M | 30.1M | 26.6M | 24.1M | 20.6M | 12.1M | 5.0M | 3.5M | 2.2M | 1.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $48.00M | $73.23M | $76.99M | $109.61M | $78.22M | $64.00M | $9.69M | $14.11M | $17.79M | $20.52M |
| Current assets | $49.38M | $74.51M | $78.26M | $110.94M | $79.75M | $64.92M | $10.09M | $14.33M | $17.84M | $22.39M |
| Goodwill | - | - | - | - | - | - | - | - | - | $100.0K |
| Total assets | $51.77M | $76.90M | $81.44M | $114.19M | $80.39M | $66.40M | $11.67M | $14.89M | $18.34M | $22.53M |
| Current liabilities | $7.97M | $8.15M | $8.49M | $10.63M | $6.84M | $4.77M | $5.34M | $6.06M | $4.67M | $4.52M |
| Long-term debt | - | - | - | - | - | - | $900.0K | - | - | - |
| Total debt | - | - | - | - | - | - | $900.0K | - | - | - |
| Total liabilities | $43.94M | $44.14M | $45.07M | $47.71M | $6.84M | $5.08M | $6.03M | $6.08M | $4.67M | $4.52M |
| Shareholders' equity | $7.83M | $32.76M | $36.38M | $66.48M | $73.55M | $61.32M | $5.64M | $8.81M | $13.67M | $18.01M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$24.58M | -$33.07M | -$47.34M | $8.64M | -$20.87M | -$21.62M | -$21.46M | -$20.57M | -$21.55M | -$20.79M |
| Capital expenditures | $104.0K | $11.0K | $153.0K | $366.0K | $133.0K | $253.0K | $64.0K | $96.1K | $24.7K | $60.0K |
| Free cash flow | -$24.68M | -$33.08M | -$47.49M | $8.28M | -$21.00M | -$21.87M | -$21.53M | -$20.67M | -$21.58M | -$20.85M |
| Investing cash flow | -$104.0K | -$11.0K | -$153.0K | -$366.0K | -$133.0K | -$253.0K | -$64.0K | -$96.1K | -$24.7K | -$109.8K |
| Financing cash flow | -$217.0K | $29.32M | $14.87M | $23.11M | $35.22M | $76.18M | $17.11M | $16.98M | $18.81M | $15.78M |
| Stock-based compensation | $9.19M | $5.29M | $3.84M | $2.79M | $1.69M | $1.25M | $1.29M | $1.80M | $3.49M | $4.30M |
| Depreciation and amortization | $173.0K | $197.0K | $207.0K | $699.0K | $524.0K | $447.0K | $420.0K | $50.7K | - | $77.5K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | -92.1% | -10.0% | - | - | - | - | - | - |
| Gross margin | - | - | - | - | 21.3% | - | - | - | - | - |
| Operating margin | -40274.4% | - | -64098.8% | -3311.1% | -2182.2% | - | - | - | - | - |
| Net margin | -37652.2% | - | -60269.1% | -3205.5% | -2165.6% | - | - | - | - | - |
| Free cash flow margin | -27426.7% | - | -58627.2% | 803.7% | -1835.6% | - | - | - | - | - |
| Return on equity | -432.6% | -116.7% | -134.2% | -49.7% | -33.7% | -36.2% | -388.0% | -268.4% | -194.6% | -135.1% |
| Return on assets | -65.5% | -49.7% | -59.9% | -28.9% | -30.8% | -33.5% | -187.7% | -158.9% | -145.1% | -108.0% |
| Current ratio | 6.20 | 9.14 | 9.21 | 10.44 | 11.66 | 13.62 | 1.89 | 2.36 | 3.82 | 4.95 |
| Debt to equity | - | - | - | - | - | - | 0.16 | - | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.00M | $0 | $0 | $90.0K | - | - | - | - | - | - | - | - |
| Research and development | $5.38M | $4.20M | $4.30M | $4.25M | $4.88M | $7.70M | $4.81M | $9.77M | $8.82M | $6.63M | $8.12M | $11.62M |
| Selling, general and admin | $2.06M | $1.70M | $2.12M | $1.53M | $2.62M | $8.94M | $2.69M | $2.83M | $3.59M | $2.96M | $2.31M | $2.73M |
| Operating income | $27.57M | -$5.90M | -$6.41M | -$5.69M | -$7.50M | -$16.64M | -$7.50M | -$12.60M | -$12.42M | -$9.60M | -$10.34M | -$14.35M |
| Net income | $27.90M | -$5.52M | -$5.94M | -$5.13M | -$6.88M | -$15.94M | -$6.65M | -$11.57M | -$11.35M | -$8.67M | -$9.32M | -$13.28M |
| EPS, basic | $0.89 | -$0.18 | -$0.20 | -$0.16 | -$0.22 | -$0.51 | -$0.21 | -$0.37 | -$0.38 | -$0.31 | -$0.33 | -$0.49 |
| EPS, diluted | $0.89 | -$0.18 | -$0.20 | -$0.16 | -$0.22 | -$0.51 | -$0.21 | -$0.37 | -$0.38 | -$0.31 | -$0.33 | -$0.49 |
| Diluted shares | 31.4M | 31.2M | - | 31.2M | 31.2M | 31.2M | - | 31.1M | 30.1M | 27.9M | - | 27.1M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $36.47M | $42.13M | $48.00M | $53.39M | $60.26M | $65.65M | $73.23M | $78.98M | $86.36M | $84.37M | $76.99M | $83.29M |
| Current assets | $37.74M | $43.26M | $49.38M | $54.37M | $61.03M | $66.46M | $74.51M | $79.52M | $87.07M | $85.37M | $78.26M | $85.60M |
| Total assets | $40.16M | $45.44M | $51.77M | $56.15M | $63.02M | $68.65M | $76.90M | $82.11M | $89.86M | $88.35M | $81.44M | $88.94M |
| Current liabilities | $9.26M | $7.35M | $7.97M | $6.83M | $8.31M | $7.11M | $8.15M | $7.75M | $9.73M | $8.06M | $8.49M | $8.67M |
| Total liabilities | $9.86M | $43.13M | $43.94M | $42.37M | $44.00M | $42.95M | $44.14M | $43.91M | $46.03M | $44.49M | $45.07M | $45.36M |
| Shareholders' equity | $30.30M | $2.30M | $7.83M | $13.78M | $19.01M | $25.69M | $32.76M | $38.21M | $43.84M | $43.86M | $36.38M | $43.58M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.18M | -$5.87M | -$5.29M | -$6.33M | -$5.39M | -$7.57M | -$5.75M | -$11.97M | -$7.97M | -$7.37M | -$7.49M | -$11.13M |
| Capital expenditures | $478.0K | $2.0K | - | - | - | - | $0 | $0 | $0 | $11.0K | $0 | $30.0K |
| Free cash flow | -$5.66M | -$5.87M | - | - | - | - | -$5.75M | -$11.97M | -$7.97M | -$7.38M | -$7.49M | -$11.15M |
| Investing cash flow | -$478.0K | -$2.0K | - | - | - | - | $0 | $0 | $0 | -$11.0K | $0 | -$30.0K |
| Financing cash flow | -$2.0K | -$3.0K | -$3.0K | -$209.0K | -$3.0K | -$2.0K | -$3.0K | $4.60M | $9.95M | $14.77M | $1.19M | $2.86M |
| Stock-based compensation | $118.0K | $11.0K | $10.0K | $109.0K | $197.0K | $8.87M | $1.20M | $1.34M | $1.37M | $1.38M | $927.0K | $921.0K |
| Depreciation and amortization | $432.0K | $29.0K | -$442.0K | $206.0K | $362.0K | $47.0K | -$410.0K | $202.0K | $189.0K | $216.0K | -$384.0K | $200.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | 78.8% | - | - | -6324.4% | - | - | - | - | - | - | - | - |
| Net margin | 79.7% | - | - | -5701.1% | - | - | - | - | - | - | - | - |
| Free cash flow margin | -16.2% | - | - | - | - | - | - | - | - | - | - | - |
| Current ratio | 4.08 | 5.89 | 6.20 | 7.96 | 7.34 | 9.35 | 9.14 | 10.25 | 8.95 | 10.59 | 9.21 | 9.87 |
Source: XBRL data Actinium Pharmaceuticals Inc. (Delaware) files with the SEC, latest filing dated Aug 7, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-30, first reported Aug 14, 2020.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ATNM peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ATNM | $35.09M | - | $11.31M | 32.2% | $48.4M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
ATNM FAQ
6 questionsWhat is ATNM revenue?
Actinium Pharmaceuticals Inc. (Delaware) (ATNM) reported $35.09M of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $90.0K.Is ATNM profitable?
Yes. Actinium Pharmaceuticals Inc. (Delaware) earned $11.31M in net income for the twelve months ended Jun 30, 2026, a net margin of 32.2%.How much cash and debt does ATNM have?
Actinium Pharmaceuticals Inc. (Delaware) reported $36.47M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is ATNM earnings per share?
Diluted earnings per share were $0.35 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did ATNM last report financial results?
The latest statements here come from Actinium Pharmaceuticals Inc. (Delaware)'s 10-Q filed on Aug 7, 2026, covering the period ended Jun 30, 2026.Where does this ATNM financial data come from?
Quantisnow builds these statements from the structured XBRL data Actinium Pharmaceuticals Inc. (Delaware) files with the SEC. It is provided for information only and is not investment advice.